LILLY FORESEES CECLOR CD IN U.S. "SOON,"
Executive Summary
LILLY FORESEES CECLOR CD IN U.S. "SOON," Chairman Randall Tobias told the Hambrecht & Quist 12th Annual Life Sciences Conference in San Francisco Jan. 11. The sustained-release, twice- daily formulation of the broad spectrum antibiotic cefaclor has been launched in Spain and the U.K. and is being reviewed by regulatory authorities in several other countries. The NDA has been pending at FDA since November 1991. The CD approval prediction is the first venture by Tobias, since joining Lilly, into the imprecise realm of FDA approval guestimates.